Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Cellular Oncology
Published in: Cellular Oncology 5/2016

01-10-2016 | Original Paper

Ovarian cancer-derived ascitic fluids induce a senescence-dependent pro-cancerogenic phenotype in normal peritoneal mesothelial cells

Authors: Justyna Mikuła-Pietrasik, Paweł Uruski, Kinga Matuszkiewicz, Sebastian Szubert, Rafał Moszyński, Dariusz Szpurek, Stefan Sajdak, Andrzej Tykarski, Krzysztof Książek

Published in: Cellular Oncology | Issue 5/2016

Login to get access

Abstract

Purpose

After the seeding ovarian cancer cells into the peritoneal cavity, ascitic fluid creates a microenvironment in which these cells can survive and disseminate. The exact nature of the interactions between malignant ascitic fluids and peritoneal mesothelial cells (HPMCs) in ovarian cancer progression has so far remained elusive. Here we assessed whether malignant ascitic fluids may promote the senescence of HPMCs and, by doing so, enhance the acquisition of their pro-cancerogenic phenotype.

Methods

Primary omentum-derived HPMCs, ovarian cancer-derived cell lines (A2780, OVCAR-3, SKOV-3), malignant ascitic fluids and benign ascitic fluids from non-cancerous patients were used in this study. Ovarian cancer cell proliferation, as well as HPMC proliferation and senescence, were determined using flow cytometry and β-galactosidase assays, respectively. Ovarian cancer cell migration was quantified using a Transwell assay. The concentrations of soluble agents in ascitic fluids, conditioned media and cell lysates were measured using DuoSet® Immunoassay Development kits.

Results

We found that HPMCs, when exposed to malignant ascitic fluids, exhibited decreased proliferation and increased senescence rates. The malignant ascitic fluids were found to contain elevated levels of HGF, TGF-β1 and GRO-1, of which HGF and GRO-1 were able to induce senescence in HPMCs. We also found that HPMCs subjected to malignant ascitic fluids or exogenously added HGF and GRO-1 stimulated ovarian cancer cell progression, which was manifested by an increased production of HA (adhesion), uPA (proliferation), IL-8 and MCP-1 (migration).

Conclusion

Our results indicate that malignant ascitic fluids may contribute to ovarian cancer progression by accelerating the senescence of HPMCs.
Literature
1.
Y. Li, K. Wang, Y. Z. Jiang, X. W. Chang, C. F. Dai, J. Zheng, 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) Inhibits human ovarian cancer cell proliferation. Cell. Oncol. 37, 429–437 (2014)CrossRef
2.
M. Momeni, T. Kalir, S. Farag, L. Chuang, D. Fishman, D. E. Burstein, Expression of H1.5 and PLZF in granulosa cell tumors and normal ovarian tissues: a short report. Cell. Oncol. 37, 229–234 (2014)CrossRef
3.
S. Patel, L. Kumar, N. Singh, Metformin and epithelial ovarian cancer therapeutics. Cell. Oncol. 38, 365–375 (2015)CrossRef
4.
5.
F. Odicino, S. Pecorelli, L. Zigliani, W. T. Creasman, History of the FIGO cancer staging system. Int. J. Gynaecol. Obstet. 101, 205–210 (2008)CrossRefPubMed
6.
E. C. Kohn, L. A. Travers, J. Kassis, U. Broome, J. Klominek, Malignant effusions are sources of fibronectin and other promigratory and proinvasive components. Diagn. Cytopathol. 33, 300–308 (2005)CrossRefPubMed
7.
I. Matte, D. Lane, C. Laplante, C. Rancourt, A. Piche, Profiling of cytokines in human epithelial ovarian cancer ascites. Am. J. Cancer Res. 2, 566–580 (2012)PubMedPubMedCentral
8.
M. R. Simpson-Abelson, J. L. Loyall, H. K. Lehman, J. L. Barnas, H. Minderman, K. L. O'Loughlin, P. K. Wallace, T. C. George, P. Peng, R. J. Kelleher Jr., K. Odunsi, R. B. Bankert, Human ovarian tumor ascites fluids rapidly and reversibly inhibit T cell receptor-induced NF-kappaB and NFAT signaling in tumor-associated T cells. Cancer Immun. 13, 14 (2013)PubMedPubMedCentral
9.
I. Matte, D. Lane, D. Bachvarov, C. Rancourt, A. Piche, Role of malignant ascites on human mesothelial cells and their gene expression profiles. BMC Cancer 14, 288 (2014)CrossRefPubMedPubMedCentral
10.
I. Matte, D. Lane, C. Laplante, P. Garde-Granger, C. Rancourt, A. Piche, Ovarian cancer ascites enhance the migration of patient-derived peritoneal mesothelial cells via cMet pathway through HGF-dependent and -independent mechanisms. Int. J. Cancer 137, 289–298 (2015)CrossRefPubMed
11.
H. A. Kenny, C. Y. Chiang, E. A. White, E. M. Schryver, M. Habis, I. L. Romero, A. Ladanyi, C. V. Penicka, J. George, K. Matlin, A. Montag, K. Wroblewski, S. D. Yamada, A. P. Mazar, D. Bowtell, E. Lengyel, Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. J. Clin. Invest. 124, 4614–4628 (2014)CrossRefPubMedPubMedCentral
12.
J. Mikula-Pietrasik, P. Sosinska, M. Kucinska, M. Murias, K. Maksin, A. Malinska, A. Ziolkowska, H. Piotrowska, A. Wozniak, K. Ksiazek, Peritoneal mesothelium promotes the progression of ovarian cancer cells in vitro and in a mice xenograft model in vivo. Cancer Lett. 355, 310–315 (2014)CrossRefPubMed
13.
K. Ksiazek, A. Jorres, J. Witowski, Senescence induces a proangiogenic switch in human peritoneal mesothelial cells. Rejuvenation. Res. 11, 681–683 (2008)
14.
K. Ksiazek, J. Mikula-Pietrasik, K. Korybalska, G. Dworacki, A. Jorres, J. Witowski, Senescent peritoneal mesothelial cells promote ovarian cancer cell adhesion: the role of oxidative stress-induced fibronectin. Am. J. Pathol. 174, 1230–1240 (2009)CrossRefPubMedPubMedCentral
15.
J. Mikula-Pietrasik, P. Sosinska, E. Naumowicz, K. Maksin, H. Piotrowska, A. Wozniak, D. Szpurek, K. Ksiazek, Senescent peritoneal mesothelium induces a pro-angiogenic phenotype in ovarian cancer cells in vitro and in a mouse xenograft model in vivo. Clin. Exp. Metastasis 33, 15–27 (2016)CrossRefPubMed
16.
K.Ksiazek, Mesothelial cell: a multifaceted model of aging. Ageing Res. Rev. 12, 595–604 (2013)
17.
J. Mikula-Pietrasik, P. Sosinska, J. Janus, B. Rubis, M. Brewinska-Olchowik, K. Piwocka, K. Ksiazek, Bystander senescence in human peritoneal mesothelium and fibroblasts is related to thrombospondin-1-dependent activation of transforming growth factor-beta1. Int. J. Biochem. Cell. Biol. 45, 2087–2096 (2013)CrossRefPubMed
18.
P. Sosinska, J. Mikula-Pietrasik, M. Ryzek, E. Naumowicz, K. Ksiazek, Specificity of cytochemical and fluorescence methods of senescence-associated beta-galactosidase detection for ageing driven by replication and time. Biogerontology 15, 407–413 (2014)CrossRefPubMedPubMedCentral
19.
J. Mikula-Pietrasik, A. Kuczmarska, M. Kucinska, M. Murias, M. Wierzchowski, M. Winckiewicz, R. Staniszewski, A. Breborowicz, K. Ksiazek, Resveratrol and its synthetic derivatives exert opposite effects on mesothelial cell-dependent angiogenesis via modulating secretion of VEGF and IL-8/CXCL8. Angiogenesis 15, 361–376 (2012)CrossRefPubMedPubMedCentral
20.
K. Lessan, D. J. Aguiar, T. Oegema, L. Siebenson, A. P. Skubitz, CD44 and beta1 integrin mediate ovarian carcinoma cell adhesion to peritoneal mesothelial cells. Am. J. Pathol. 154, 1525–1537 (1999)CrossRefPubMedPubMedCentral
21.
C. Bolitho, M. A. Hahn, R. C. Baxter, D. J. Marsh, The chemokine CXCL1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor. Endocr. Relat. Cancer 17, 929–940 (2010)
22.
K.Fischer, V.Lutz, O.Wilhelm, M.Schmitt, H.Graeff, P.Heiss, T.Nishiguchi, N.Harbeck, H.Kessler, T.Luther, V.Magdolen, U.Reuning, Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function. FEBS Lett. 438, 101–105 (1998)
23.
N. Said, M. J. Socha, J. J. Olearczyk, A. A. Elmarakby, J. D. Imig, K. Motamed, Normalization of the ovarian cancer microenvironment by SPARC. Mol. Cancer Res. 5, 1015–1030 (2007)CrossRefPubMed
24.
Y. Wang, J. Yang, Y. Gao, Y. Du, L. Bao, W. Niu, Z. Yao, Regulatory effect of e2, IL-6 and IL-8 on the growth of epithelial ovarian cancer cells. Cell. Mol. Immunol. 2, 365–372 (2005)PubMed
25.
Y. Hirashima, H. Kobayashi, M. Suzuki, Y. Tanaka, N. Kanayama, T. Terao, Transforming growth factor-beta1 produced by ovarian cancer cell line HRA stimulates attachment and invasion through an up-regulation of plasminogen activator inhibitor type-1 in human peritoneal mesothelial cells. J. Biol. Chem. 278, 26793–26802 (2003)CrossRefPubMed
26.
S. Furukawa, S. Soeda, Y. Kiko, O. Suzuki, Y. Hashimoto, T. Watanabe, H. Nishiyama, K. Tasaki, H. Hojo, M. Abe, K. Fujimori, MCP-1 promotes invasion and adhesion of human ovarian cancer cells. Anticancer Res. 33, 4785–4790 (2013)PubMed
27.
N. Ahmed, K. L. Stenvers, Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. Front. Oncol. 3, 256 (2013)CrossRefPubMedPubMedCentral
28.
J. Mikula-Pietrasik, P. Sosinska, K. Maksin, M. G. Kucinska, H. Piotrowska, M. Murias, A. Wozniak, D. Szpurek, K. Ksiazek, Colorectal cancer-promoting activity of the senescent peritoneal mesothelium. Oncotarget 6, 29178–29195 (2015)PubMedPubMedCentral
29.
G. D'Andrilli, A. Giordano, A. Bovicelli, Epithelial ovarian cancer: the role of cell cycle genes in the different histotypes. Open. Clin. Cancer J. 2, 7–12 (2008)CrossRefPubMed
30.
G. V. Raghuram, P. K. Mishra, Stress induced premature senescence: a new culprit in ovarian tumorigenesis? Indian J. Med. Res. 140(Suppl) S120–S129 (2014)PubMedPubMedCentral
31.
K. Lohani, S. Shetty, P. Sharma, V. Govindarajan, P.Thomas, B.Loggie, Pseudomyxoma peritonei: inflammatory responses in the peritoneal microenvironment. Ann. Surg. Oncol. 21, 1441–1447 (2014)CrossRefPubMed
32.
S.Judge, P.Thomas, V. Govindarajan, P. Sharma, B. Loggie, Malignant peritoneal mesothelioma: characterization of the inflammatory response in the tumor microenvironment. Ann. Surg. Oncol. 23, 1496–1500 (2016)CrossRef
33.
C. Frippiat, Q. M. Chen, S. Zdanov, J. P. Magalhaes, J. Remacle, O. Toussaint, Subcytotoxic H2O2 stress triggers a release of transforming growth factor-beta 1, which induces biomarkers of cellular senescence of human diploid fibroblasts. J. Biol. Chem. 276, 2531–2537 (2001)CrossRefPubMed
34.
R. Tremain, M. Marko, V. Kinnimulki, H. Ueno, E. Bottinger, A. Glick, Defects in TGF-beta signaling overcome senescence of mouse keratinocytes expressing v-Ha-ras. Oncogene 19, 1698–1709 (2000)CrossRefPubMed
35.
G. Yang, D. G. Rosen, Z. Zhang, R. C. Bast Jr., G. B. Mills, J. A. Colacino, I. Mercado-Uribe, J. Liu, The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc. Natl. Acad. Sci. USA 103, 16472–16477 (2006)CrossRefPubMedPubMedCentral
36.
M. Miyazaki, E. Gohda, K. Kaji, M. Namba, Increased hepatocyte growth factor production by aging human fibroblasts mainly due to autocrine stimulation by interleukin-1. Biochem. Biophys. Res. Commun. 246, 255–260 (1998)
37.
M. Mariani, M. McHugh, M. Petrillo, S. Sieber, S. He, M. Andreoli, Z. Wu, P. Fiedler, G. Scambia, S. Shahabi, C. Ferlini, HGF/c-met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer. Oncotarget 5, 4855–4867 (2014)CrossRefPubMedPubMedCentral
38.
A. Elkhattouti, M. Hassan, C. R. Gomez, Stromal Fibroblast in Age-Related Cancer: Role in Tumorigenesis and Potential as Novel Therapeutic Target. Front. Oncol. 5, 158 (2015)CrossRefPubMedPubMedCentral
39.
S. Domcke, R. Sinha, D. A. Levine, C. Sander, N. Schultz, Evaluating cell lines as tumour models by comparison of genomic profiles. Nat. Commun. 4, 2126 (2013)CrossRefPubMedPubMedCentral
40.
A. R. Davalos, J. P. Coppe, J. Campisi, P. Y. Desprez, Senescent cells as a source of inflammatory factors for tumor progression. Cancer Metastasis Rev. 29, 273–283 (2010)CrossRefPubMedPubMedCentral
Metadata
Title
Ovarian cancer-derived ascitic fluids induce a senescence-dependent pro-cancerogenic phenotype in normal peritoneal mesothelial cells
Authors
Justyna Mikuła-Pietrasik
Paweł Uruski
Kinga Matuszkiewicz
Sebastian Szubert
Rafał Moszyński
Dariusz Szpurek
Stefan Sajdak
Andrzej Tykarski
Krzysztof Książek
Publication date
01-10-2016
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 5/2016
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-016-0289-1

Other articles of this Issue 5/2016

Cellular Oncology 5/2016 Go to the issue

Original Paper

MGMT DNA repair gene promoter/enhancer haplotypes alter transcription factor binding and gene expression

Original Paper

Hypoxia-inducible microRNA-488 regulates apoptosis by targeting Bim in osteosarcoma

Review

The role of lymphangiogenesis and angiogenesis in tumor metastasis

Original Paper

Nitric oxide increases the migratory activity of non-small cell lung cancer cells via AKT-mediated integrin αv and β1 upregulation

Report

A network including PU.1, Vav1 and miR-142-3p sustains ATRA-induced differentiation of acute promyelocytic leukemia cells - a short report

Original Paper

Hypoxia can impair doxorubicin resistance of non-small cell lung cancer cells by inhibiting MRP1 and P-gp expression and boosting the chemosensitizing effects of MRP1 and P-gp blockers
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits